Antonio Mafrici
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Antonio Mafrici has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Gabriele Tumminello
Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
4 shared publications - Lucia Barbieri
Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
3 shared publications - Stefano Carugo
Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
3 shared publications - Stefano Lucreziotti
Cardiology Unit, ASST Santi Paolo e Carlo, 20153 Milan, Italy
3 shared publications - Alberto Cereda
Cardiology Unit, ASST Santi Paolo e Carlo, 20153 Milan, Italy
2 shared publications Barbara Conconi
Division of Cardiology, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy
2 shared publications
Latest Publications
- Open Access
- 7 October 2021
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 8 (10) , 129
Meta-Analysis of Placebo-Controlled Trials of Levosimendan in Acute Myocardial Infarction
The treatment of acute myocardial infarction is early revascularization. Heart failure and cardiogenic shock may complicate acute myocardial infarction despite applying the best available strategy. Levosimendan is a relatively new drug to treat heart failure with a peculiar mechanism of action: calcium sensitization of myocardial fibres. Levosimendan has a direct inotropic effect but also pleiotropic effects; through the K+ATP channel’s opening, it also has a vasodilator effect which may participate concretely in the global effects of the drug. The focus of the literature is on the anti-heart failure and anti-cardiogenic shock properties of Levosimendan, but it may have effects also preventing the development of myocardial insufficiency in acute myocardial infarction. The aim of the meta-analysis is to evaluate the effect of Levosimendan on acute myocardial infarction in placebo-controlled trials. Based on the eight studies selected, we found a beneficial effect of Levosimendan on acute and long-term mortality of patients affected by acute myocardial infarction. With caution in interpreting the results of this meta-analysis, our data support the idea that Levosimendan may already have a role in the treatment of acute ischemic heart disease. Further studies specifically designed to investigate the early role in the treatment of ischemic heart failure are needed.
- 7 October 2021
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 8 (10) , 129
Open AccessMeta-Analysis of Placebo-Controlled Trials of Levosimendan in Acute Myocardial Infarction
The treatment of acute myocardial infarction is early revascularization. Heart failure and cardiogenic shock may complicate acute myocardial infarction despite applying the best available strategy. Levosimendan is a relatively new drug to treat heart failure with a peculiar mechanism of action: calcium sensitization of myocardial fibres. Levosimendan has a direct inotropic effect but also pleiotropic effects; through the K+ATP channel’s opening, it also has a vasodilator effect which may participate concretely in the global effects of the drug. The focus of the literature is on the anti-heart failure and anti-cardiogenic shock properties of Levosimendan, but it may have effects also preventing the development of myocardial insufficiency in acute myocardial infarction. The aim of the meta-analysis is to evaluate the effect of Levosimendan on acute myocardial infarction in placebo-controlled trials. Based on the eight studies selected, we found a beneficial effect of Levosimendan on acute and long-term mortality of patients affected by acute myocardial infarction. With caution in interpreting the results of this meta-analysis, our data support the idea that Levosimendan may already have a role in the treatment of acute ischemic heart disease. Further studies specifically designed to investigate the early role in the treatment of ischemic heart failure are needed.
- Open Access
- 5 July 2021
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 25 (7) , 522-523
Acute myocarditis after the second dose of SARS-CoV-2 vaccine: Serendipity or atypical causal relationship?
- 5 July 2021
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 25 (7) , 522-523
Open AccessAcute myocarditis after the second dose of SARS-CoV-2 vaccine: Serendipity or atypical causal relationship?
- Open Access
- 1 December 2020
- Published by Edizioni Minerva Medica in Italian Journal of Emergency Medicine
- Vol. 9 (3)
ST-segment elevation myocardial infarction care during the COVID-19 health emergency: the organization of one Hub center in Milan, Italy
- 1 December 2020
- Published by Edizioni Minerva Medica in Italian Journal of Emergency Medicine
- Vol. 9 (3)
Open AccessST-segment elevation myocardial infarction care during the COVID-19 health emergency: the organization of one Hub center in Milan, Italy
- Open Access
- 1 October 2020
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 30
Impact of COVID-19 on STEMI: Second youth for fibrinolysis or time to centralized approach?
- 1 October 2020
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 30
Open AccessImpact of COVID-19 on STEMI: Second youth for fibrinolysis or time to centralized approach?